647 related articles for article (PubMed ID: 34290693)
1. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase.
Shi Y; Ju M; Zhang Y; Liang L; Sun X; Di X
Medicine (Baltimore); 2024 Mar; 103(12):e37362. PubMed ID: 38518034
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis.
Zhao Z; Yang Y; Liu Z; Chen H; Guan X; Jiang Z; Yang M; Liu H; Chen T; Gao Y; Zou S; Wang X
Front Mol Biosci; 2022; 9():951636. PubMed ID: 36188226
[No Abstract] [Full Text] [Related]
5. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types.
Liu T; Zhang J; Lin C; Liu G; Xie G; Dai Z; Yu P; Wang J; Guo L
Front Cell Dev Biol; 2022; 10():839136. PubMed ID: 35372330
[No Abstract] [Full Text] [Related]
7. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive pancancer analysis reveals the potential value of RAR-related orphan receptor C (RORC) for cancer immunotherapy.
He S; Yu J; Sun W; Sun Y; Tang M; Meng B; Liu Y; Li J
Front Genet; 2022; 13():969476. PubMed ID: 36186454
[No Abstract] [Full Text] [Related]
9. Gene Expression Profiling Identifies Cell Proliferation and Inflammation as the Predominant Pathways Regulated by Aryl Hydrocarbon Receptor in Primary Human Fetal Lung Cells Exposed to Hyperoxia.
Shivanna B; Maity S; Zhang S; Patel A; Jiang W; Wang L; Welty SE; Belmont J; Coarfa C; Moorthy B
Toxicol Sci; 2016 Jul; 152(1):155-68. PubMed ID: 27103661
[TBL] [Abstract][Full Text] [Related]
10. Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.
Kim DK; Lee CY; Han YJ; Park SY; Han H; Na K; Kim MH; Yang SM; Baek S; Kim Y; Hwang JY; Lee S; Kang SS; Hong MH; Lim SM; Lee JB; Kim JH; Cho BC; Pyo KH
Front Immunol; 2024; 15():1330228. PubMed ID: 38680496
[TBL] [Abstract][Full Text] [Related]
11. The Aryl Hydrocarbon Receptor and Tumor Immunity.
Xue P; Fu J; Zhou Y
Front Immunol; 2018; 9():286. PubMed ID: 29487603
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic Value of Transcription Factor 19 (TCF19) Associated with Renal Clear Cell Carcinoma: A Comprehensive Analysis of 33 Human Cancer Cases.
Cheng X; Hou J; Wen X; Dong R; Lu Z; Jiang Y; Wu G; Yuan Y
J Oncol; 2022; 2022():1488165. PubMed ID: 36111242
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
14. The role of AhR in transcriptional regulation of immune cell development and function.
Trikha P; Lee DA
Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188335. PubMed ID: 31816350
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
16. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide mapping and analysis of aryl hydrocarbon receptor (AHR)- and aryl hydrocarbon receptor repressor (AHRR)-binding sites in human breast cancer cells.
Yang SY; Ahmed S; Satheesh SV; Matthews J
Arch Toxicol; 2018 Jan; 92(1):225-240. PubMed ID: 28681081
[TBL] [Abstract][Full Text] [Related]
19. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
[No Abstract] [Full Text] [Related]
20. CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers.
Zhang H; Yang Z; Du G; Cao L; Tan B
Technol Cancer Res Treat; 2021; 20():1533033820980088. PubMed ID: 33576304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
